Orphazyme withdraws marketing application ahead of final vote

On Tuesday, biotech company Orphazyme announced that it is withdrawing its European marketing application for arimoclomol within the Niemann-Pick type C indication, ahead of the final vote of an EMA expert committee.

Biotech company Orphazyme has decided to withdraw its European marketing authorization application for its drug hope, arimoclomol, a potential treatment for Niemann-Pick type C (NPC), a company press release reports.

This falls before the European Medicines Agency’s (EMA) special committee, the CHMP, was slated to vote officially on whether to recommend the drug for approval later this month. Based on a trend vote following a February meeting with the committee, Orphazyme was not expecting the drug to be approved.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs